Please login to the form below

Not currently logged in

Ferrer pulls EU application for Egrifta in HIV patients with excess tissue

Comes after EMA committee was unable to determine positive benefit to risk balance on current data

Ferrer Internacional has withdrawn its application to market Egrifta (tesamorelin) in the EU for the treatment of patients with HIV who have a build-up of fat around their internal organs.

The European Medicines Agency (EMA) said the Spanish pharma company decided to pull its application after the regulator's advisory committee was unable to determine whether the drug had a positive benefit to risk balance based on available data.

The application, which was originally submitted to the EMA in May 2011, was for the drug's use in patients with visceral adipose tissue (VAT) levels greater than 130cm2.

Excess VAT, or lipodystrophy, is a known complication of HIV infection and has been linked to some antiretroviral drugs.

It can cause a patient's abdomen to protrude excessively, and there is concern it can lead to other problems, such as cardiovascular disease, type 2 diabetes and other obesity-related conditions.

Egrifta became the first drug available in the US to treat the condition in November, 2010, when it gained approval from the Food and Drug Administration (FDA).

It is marketed in the country by EMD Serono, an affiliate of Germany's Merck KGaA, who bought regional rights to the drug from its original developers Theratechnologies in a deal potentially worth up to $215m.

EMD Serono also has an option to participate in future indications in the US, with Theratechnologies maintaining the right to co-promote Egrifta in its additional uses.

The drug's US approval was based on placebo-controlled studies that demonstrated patients with HIV and excess abdominal fat treated with Egrifta experienced greater reductions in abdominal fat as measured by CT scan than were experienced by patients given a placebo injection.

The reasons why Ferrer failed in Europe where EMD succeeded in the US should become clearer next when when more information will be made avaialble after the next meeting of the EMA's Committee for Medicinal Products for Human Use (CHMP).

28th June 2012


Featured jobs

Subscribe to our email news alerts


Add my company

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...